相关实验视频

Updated: Sep 16, 2025

Author Spotlight: Exploring the Impact of Reduced Resistance Exercise Volume on Metabolic Health

Author Spotlight: Exploring the Impact of Reduced Resistance Exercise Volume on Metabolic Health

Published on: December 1, 2023

清晨升高的胰岛素增强了下午的食后胰岛素作用和葡萄糖的有效性

Hannah L Waterman¹, Marta S Smith¹, Ben Farmer¹

¹Department of Molecular Physiology & Biophysics, Vanderbilt University School of Medicine.

bioRxiv : the preprint server for biology

|July 9, 2025

概括

早晨的胰岛素原始化增强了肝脏对第二顿饭的葡萄糖吸收反应. 这种原始化改善了胰岛素作用和葡萄糖的有效性,这表明胰岛素和葡萄糖信号的共同细胞点.

科学领域:

代谢生理学代谢生理学
内分泌学在内分泌学.
葡萄糖的恒常性葡萄糖的恒常性

背景情况:

第二餐现象描述了第二次相同的饭后血糖反应的改善.
肝脏葡萄糖吸收 (HGU) 是由胰岛素作用,葡萄糖有效性和门葡萄糖信号来调节的.
之前的研究强调了早晨高胰岛素血症在为晚些时候的HGU预备肝脏的作用.

研究的目的:

为了研究早晨胰岛素对下午血糖反应的影响.
确定早晨高胰岛素血清如何影响下午的胰岛素作用,葡萄糖的有效性和门葡萄糖信号.
阐明第二餐效应背后的机制.

主要方法:

狗接受了四小时的早晨高胰岛素血压 (Prime) 或基础胰岛素输送 (No Prime).
经过1.5小时的非紧期后,两组都接受了下午的高血糖紧,并提供了门口葡萄糖信号.
在基础胰岛素条件下,在下午的时测量了净肝血糖摄取量 (HGU).

主要成果:

与没有prime组相比,早上胰岛素主要在下午紧期间显著提高净HGU (2.2vs0.1mg/kg/min).
这种增强表明化组的葡萄糖有效性和/或门葡萄糖信号有所改善.
早晨的胰岛素原始化同样增强了下午的胰岛素作用和葡萄糖有效性 (包括门葡萄糖信号).

结论:

早晨的胰岛素高血压会促使肝脏提高对随后的饮食的血糖反应.
原始效应涉及改善胰岛素作用和葡萄糖的有效性.
这表明,早晨的胰岛素激活了葡萄糖信号利用的细胞通路,为未来的代谢挑战做好肝脏的准备.

关键词:

斯塔布-特劳戈特效应是一个效应.早餐早餐早餐早餐早餐.葡萄糖是一种葡萄糖.葡萄糖葡萄糖葡萄糖是一种葡萄糖的有效性.葡萄糖的新陈代谢.糖原糖原是一种糖原.肝脏摄取葡萄糖的时间在这种情况下,胰岛素胰岛素.胰岛素作用的胰岛素作用胰岛素的信号传递方式肝脏代谢肝脏代谢午餐午餐午餐午餐午餐食组成食组成吃饭后的饮食方式第二顿饭的影响.第二餐的现象.

更多相关视频

Hyperinsulinemic-euglycemic Clamps in Conscious, Unrestrained Mice

Hyperinsulinemic-euglycemic Clamps in Conscious, Unrestrained Mice

Published on: November 16, 2011

Improving IV Insulin Administration in a Community Hospital

Improving IV Insulin Administration in a Community Hospital

Published on: June 11, 2012

相关概念视频

Insulin: Dosing Regimen and Adverse Effects

Insulin: Dosing Regimen and Adverse Effects

Insulin-replacement therapy usually includes both long-acting insulin (basal) and short-acting insulin (to cater to postprandial needs). In a diverse group of type 1 diabetes patients, the average daily insulin dose is typically 0.5-0.7 units/kg body weight. However, obese patients and pubertal adolescents may need more due to insulin resistance.
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...

Oral Hypoglycemic Agents: Glinides

Oral Hypoglycemic Agents: Glinides

Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...

Hormones Regulating Blood Glucose

Hormones Regulating Blood Glucose

Insulin is released by beta cells of the pancreas when blood glucose levels are high. It facilitates glucose absorption and utilization in insulin-dependent cells with insulin receptors on their plasma membranes. Insulin promotes glucose uptake by increasing the number of glucose transport proteins in the cell membrane, allowing glucose to enter the cell. As a result, glucose utilization and ATP production are enhanced.
In addition to accelerating glucose uptake and utilization, insulin has...

Glucagon-like Receptor Agonists

Glucagon-like Receptor Agonists

Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...

Dipeptidyl Peptidase 4 Inhibitors

Dipeptidyl Peptidase 4 Inhibitors

Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...

Oral Hypoglycemic Agents: Biguanides and Glitazones

Oral Hypoglycemic Agents: Biguanides and Glitazones

Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...